Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00569855 · ClinicalTrials.gov registry record · Phase 2

Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery

A Phase 2 study of Cardiopulmonary Bypass and Open Heart Surgery, sponsored by University of Arkansas.

Completed
Registry status
Phase 2
Development phase
785
Enrollment target
1
Study location

NCT00569855 is a Phase 2 study of Cardiopulmonary Bypass and Open Heart Surgery that has completed, run by University of Arkansas. The registered enrollment target is 785 participants, above the 657-participant average among 9 other Cardiopulmonary Bypass trials with a reported enrollment target (19% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00569855, a Phase 2 study of Cardiopulmonary Bypass and Open Heart Surgery, has completed, sponsored by University of Arkansas.

COMPLETED
Registry status
Phase 2
Development phase
785 participants
Enrollment target
1
Study location

Study Summary

Cardiopulmonary bypass is done with a machine that does the work of the heart and lungs during open-heart surgery. This study is to determine if intravenous (i.v.) phenoxybenzamine is safe. This drug lowers the blood pressure, making it easier for the cardiopulmonary bypass machine to deliver blood and oxygen to all of the organs and tissues.

Interventions

  • DRUG Phenoxybenzamine

Study Locations (1)

Arkansas

  • Arkansas Children's Hospital - Little Rock

Trial Details

FieldValue
Enrollment Target 785 participants
Start Date 2001-02
Est. Completion 2010-08
Phase Phase 2

Sponsor

University of Arkansas

318 total trials

What the Registry Record Tells You About NCT00569855

The ClinicalTrials.gov registry entry for NCT00569855 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 785 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 9 other Cardiopulmonary Bypass trials with a reported enrollment target (19% higher). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cardiopulmonary Bypass appearing as the primary indexed condition, and to 1 intervention - of which Phenoxybenzamine is the first listed.

NCT00569855 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.

Frequently Asked Questions

What is clinical trial NCT00569855 about?

NCT00569855 is a clinical study titled "Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery". Cardiopulmonary bypass is done with a machine that does the work of the heart and lungs during open-heart surgery. This study is to determine if intravenous (i.v.) phenoxybenzamine is safe. This drug lowers the blood pressure, making it easier for the cardiopulmonary bypass machine to deliver blood ...

What is the current status of trial NCT00569855?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 785 participants. The study started on 2001-02. Estimated completion is 2010-08.

What conditions does trial NCT00569855 study?

This clinical trial studies the following conditions: Cardiopulmonary Bypass, Open Heart Surgery.

What interventions are being tested in trial NCT00569855?

The interventions under investigation include: Phenoxybenzamine (DRUG).

Who is sponsoring clinical trial NCT00569855?

This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00569855 being conducted?

This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiopulmonary Bypass

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.